Medische Oncologie Nummer 5, pp. 24-27
nov 2007, jaargang 10
Medische Oncologie Nr. 5, pp. 24-27
nov 2007, jr. 10
Wetenschap

Lapatinib: een alternatief voor trastuzumab?

Binnen de medische oncologie is momenteel veel belangstelling voor de toepassingsmogelijkheden van lapatinib bij mammacarcinoom. De vraag is hoe tot op heden gepresenteerde studieresultaten moeten worden geïnterpreteerd en derhalve uitsluitsel kunnen geven over de huidige plaats als aanvulling op of alternatief voor trastuzumab bij de mammacarcinoombehandeling. En wat zeggen studieresultaten over de effectiviteit van lapatinib bij andere solide tumoren?

Referenties

  1. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. Slamon DJ, LeylandJones B, Shak S, et al.N Engl J Med2001;344:783-92.
  2. Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Valabrega G, Montemurro F, Aglietta M.Ann Oncol2007;18:977-84.
  3. Trastuzumab – mechanism of action and use in clinical practice. Hudis CA.N Engl J Med2007;357:39-51. 
  4. Cardiac dysfunction in the trastuzumab clinical trials experience. Seidman A, Hudis C, Pierri M, et al.J Clin Oncol2002;20:1215-21.
  5. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. Geyer C, Forster J, Lindquist D, et al.N Engl J Med2006;355:2733-43.
  6. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. Burris H, Hurwitz H, Dees EC, et al.J Clin Oncol2005;23: 5305-13.
  7. A unique structure for epidermal growth factor receptor bound to GW572016 (lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Wood E, Truesdale A, McDonald O, et al.Cancer Res2004;64:6652-9.
  8. Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib. Burris H.Oncologist 2004;9:10-5.
  9. Lapatinib: current status and future directions in breast cancer. Moy B, Goss PE.Oncologist2006;11:1047-57. 
  10. Does lapatinib, a small-molecule tyrosine kinase inhibitor, constitute a breakthrough in the treatment of breast cancer? Ito Y, Tokudome N, Sugihara T, et al.Breast Cancer2007;14:156-62.
  11. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. Scaltriti M, Rojo F, Ocana A, et al.J Natl Cancer Inst2007;99:628-38.
  12. Lapatinib-associated toxicity and practical management recommendations. Moy B, Goss P.Oncologist2007;12:756-65. 
  13. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. Piccart-Gebhart M, Procter M, Leyland-Jones B, et al.N Engl J Med 2005;353:1659-72.
  14. Results of an analysis of cardiac function in 2,812 patients treated with lapatinib. Perez EA, Byrne JA, Hammond IW.J Clin Oncol2006;24:583.
  15. Cardiac safety in patients (pts) with metastatic breast cancer (MBC) treated with lapatinib (L) and trastuzumab (TRA). Storniolo AM,Koehler M, Preston A, et al.J Clin Oncol2007;25:514.
  16. A phase II, open-label, multicenter study of lapatinib in two cohorts of patients with advanced or metastatic breast cancer who have progressed while receiving trastuzumab-containing regimens. Burstein H, Storniolo AM, Franco S, et al.Ann Oncol2004;15:A1040.
  17. A phase II, open-label, multicenter study of GW572016 in patients with trastuzumab-refractory metastatic breast cancer. Blackwell KL, Kaplan EH, Franco SX, et al.J Clin Oncol2004;22:3006.
  18. Phase II clinical study of lapatinib (GW572016) in patients with advanced or metastatic breast cancer. Iwata H, Toi M, Fujiwara Y, et al. Breast Cancer Res Treat2006;100:S68.
  19. EGF103009, a phase II trial of lapatinib monotherapy in patients with relapsed/refractory inflammatory breast cancer (IBC): clinical activity and biologic predictors of response. Spector NL, Blackwell K, Hurley J, et al.J Clin Oncol2006;24:502.
  20. Phase II trial of lapatinib for brain metastases in patients with HER2+ breast cancer. Lin NU, Carey LA, Liu MC, et al.J Clin Oncol2006;24:503.
  21. Lapatinib (L) plus capecitabine (C) in HER2+ advanced breast cancer (ABC): report of updated effecicay and gene-array data. Crown J, Cameron D, Martin AM.Eur J Cancer Supplements2007;5:212.
  22. Efficacy of lapatinib in patients with high tumor EGFR expression: results of a phase III trial in advanced renal cell carcinoma (RCC). Ravaud A, Gardner J, Hawkins R, et al.J Clin Oncol2006;24:4502.
  23. Phase II study of lapatinib, a dual inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase 1 and 2 (Her2/Neu) in patients (pts) with advanced biliary tree cancer (BTC) or hepatocellular cancer (HCC). A California Consortium (CCC-P) Trial. Ramanathan RK, Belani CP, Singh DA, et al.J Clin Oncol2006;24:4010. 
  24. GW572016, gemcitabine and GW572016, gemcitabine, oxaliplatin, a two-stage, phase I study for advanced pancreaticobiliary cancer. Safran H, Iannitti D, Miner T, et al.J Clin Oncol2006;24:4002.
Wetenschap

Lapatinib: een alternatief voor trastuzumab?

Binnen de medische oncologie is momenteel veel belangstelling voor de toepassingsmogelijkheden van lapatinib bij mammacarcinoom. De vraag is hoe tot op heden gepresenteerde studieresultaten moeten worden geïnterpreteerd en derhalve uitsluitsel kunnen geven over de huidige plaats als aanvulling op of alternatief voor trastuzumab bij de mammacarcinoombehandeling. En wat zeggen studieresultaten over de effectiviteit van lapatinib bij andere solide tumoren?

Referenties

  1. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. Slamon DJ, LeylandJones B, Shak S, et al.N Engl J Med2001;344:783-92.
  2. Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Valabrega G, Montemurro F, Aglietta M.Ann Oncol2007;18:977-84.
  3. Trastuzumab – mechanism of action and use in clinical practice. Hudis CA.N Engl J Med2007;357:39-51. 
  4. Cardiac dysfunction in the trastuzumab clinical trials experience. Seidman A, Hudis C, Pierri M, et al.J Clin Oncol2002;20:1215-21.
  5. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. Geyer C, Forster J, Lindquist D, et al.N Engl J Med2006;355:2733-43.
  6. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. Burris H, Hurwitz H, Dees EC, et al.J Clin Oncol2005;23: 5305-13.
  7. A unique structure for epidermal growth factor receptor bound to GW572016 (lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Wood E, Truesdale A, McDonald O, et al.Cancer Res2004;64:6652-9.
  8. Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib. Burris H.Oncologist 2004;9:10-5.
  9. Lapatinib: current status and future directions in breast cancer. Moy B, Goss PE.Oncologist2006;11:1047-57. 
  10. Does lapatinib, a small-molecule tyrosine kinase inhibitor, constitute a breakthrough in the treatment of breast cancer? Ito Y, Tokudome N, Sugihara T, et al.Breast Cancer2007;14:156-62.
  11. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. Scaltriti M, Rojo F, Ocana A, et al.J Natl Cancer Inst2007;99:628-38.
  12. Lapatinib-associated toxicity and practical management recommendations. Moy B, Goss P.Oncologist2007;12:756-65. 
  13. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. Piccart-Gebhart M, Procter M, Leyland-Jones B, et al.N Engl J Med 2005;353:1659-72.
  14. Results of an analysis of cardiac function in 2,812 patients treated with lapatinib. Perez EA, Byrne JA, Hammond IW.J Clin Oncol2006;24:583.
  15. Cardiac safety in patients (pts) with metastatic breast cancer (MBC) treated with lapatinib (L) and trastuzumab (TRA). Storniolo AM,Koehler M, Preston A, et al.J Clin Oncol2007;25:514.
  16. A phase II, open-label, multicenter study of lapatinib in two cohorts of patients with advanced or metastatic breast cancer who have progressed while receiving trastuzumab-containing regimens. Burstein H, Storniolo AM, Franco S, et al.Ann Oncol2004;15:A1040.
  17. A phase II, open-label, multicenter study of GW572016 in patients with trastuzumab-refractory metastatic breast cancer. Blackwell KL, Kaplan EH, Franco SX, et al.J Clin Oncol2004;22:3006.
  18. Phase II clinical study of lapatinib (GW572016) in patients with advanced or metastatic breast cancer. Iwata H, Toi M, Fujiwara Y, et al. Breast Cancer Res Treat2006;100:S68.
  19. EGF103009, a phase II trial of lapatinib monotherapy in patients with relapsed/refractory inflammatory breast cancer (IBC): clinical activity and biologic predictors of response. Spector NL, Blackwell K, Hurley J, et al.J Clin Oncol2006;24:502.
  20. Phase II trial of lapatinib for brain metastases in patients with HER2+ breast cancer. Lin NU, Carey LA, Liu MC, et al.J Clin Oncol2006;24:503.
  21. Lapatinib (L) plus capecitabine (C) in HER2+ advanced breast cancer (ABC): report of updated effecicay and gene-array data. Crown J, Cameron D, Martin AM.Eur J Cancer Supplements2007;5:212.
  22. Efficacy of lapatinib in patients with high tumor EGFR expression: results of a phase III trial in advanced renal cell carcinoma (RCC). Ravaud A, Gardner J, Hawkins R, et al.J Clin Oncol2006;24:4502.
  23. Phase II study of lapatinib, a dual inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase 1 and 2 (Her2/Neu) in patients (pts) with advanced biliary tree cancer (BTC) or hepatocellular cancer (HCC). A California Consortium (CCC-P) Trial. Ramanathan RK, Belani CP, Singh DA, et al.J Clin Oncol2006;24:4010. 
  24. GW572016, gemcitabine and GW572016, gemcitabine, oxaliplatin, a two-stage, phase I study for advanced pancreaticobiliary cancer. Safran H, Iannitti D, Miner T, et al.J Clin Oncol2006;24:4002.
Over dit artikel
Auteurs
Gabe Sonke, Sabine Linn
Over de auteurs

Gabe Sonke, internist, oncoloog in opleiding, Sabine Linn, internist-oncoloog

E-pubdatum
20 november 2007
ISSN online
2405-4763


Over dit artikel
Auteurs
Gabe Sonke, Sabine Linn
Over de auteurs

Gabe Sonke, internist, oncoloog in opleiding, Sabine Linn, internist-oncoloog

E-pubdatum
20 november 2007
ISSN online
2405-4763